Eiger BioPharmaceuticals, Inc. (EIGR)
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.
Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.
The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia.
Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
2155 Park Blvd
Palo Alto, California 94306-1543
|Phone||650 272 6138|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|David A. Cory M.B.A., MBA, R.Ph, R.Ph.||Business Founder, President, Chief Executive Officer and Director|
|Dr. Jeffrey S. Glenn M.D., Ph.D.||Scientific Founder and Independent Director|
|Sriram Ryali M.B.A.||Chief Financial Officer|
|Eldon C. Mayer III, M.B.A.||Executive Vice President and Chief Commercial Officer|
|Christopher A. Kurtz||Chief Technical Officer|
|Erik Atkisson||General Counsel, Corporate Secretary and Chief Compliance Officer|
|Dr. Ingrid C. Choong||Senior Vice President of Clinical Development|
|Dr. Stephana E. Patton J.D., Ph.D.||Consultant|
|Rich Franco M.B.A.||Senior Vice President of Regulatory Affairs|
|Dr. Colin Hislop M.D.||Senior Vice President of Clinical and Development Operations|
Latest SEC Filings
|Aug 4, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Aug 4, 2022||8-K||Current report|
|Jul 19, 2022||4||Statement of changes in beneficial ownership of securities|
|Jul 19, 2022||3||Initial statement of beneficial ownership of securities|
|Jul 18, 2022||8-K||Current report|
|Jun 21, 2022||8-K||Current report|
|Jun 7, 2022||8-K||Current report|
|May 11, 2022||SC 13G/A||Statement of acquisition of beneficial ownership by individuals|
|May 5, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 5, 2022||8-K||Current report|